Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227404 · ClinicalTrials.gov registry record
Evaluation of Point-of-Care (EPOC) for COVID-19
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 330
- Enrollment target
NCT05227404: Completed study, sponsored by University of Minnesota.
NCT05227404 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 330 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05227404 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 330 participants
- Enrollment target
Study Summary
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.
Primary Outcome
LumiraDx test and GenScript assay are two ways to determine the presence of antibodies to SARS-CoV-2. This measure is a comparison to check agreement between the two tests' results. This is a comparison of the proportion of the positive tests. The comparison is made by looking at the difference of the two proportions obtained by the two tests, so the measure is unitless.
Interventions
- DIAGNOSTIC_TEST LumiraDX
- DIAGNOSTIC_TEST RightSign
- DIAGNOSTIC_TEST Case Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2022-04-08 |
| Est. Completion | 2022-09-02 |
What the finished NCT05227404 record still lists
NCT05227404 is an observational study that tracks outcomes without assigning an intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which LumiraDX is the first listed.
NCT05227404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05227404 about?
NCT05227404 is a clinical study titled "Evaluation of Point-of-Care (EPOC) for COVID-19". EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtai...
What is the current status of trial NCT05227404?
This trial is currently completed. The enrollment target is 330 participants. The study started on 2022-04-08. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT05227404?
The interventions under investigation include: LumiraDX (DIAGNOSTIC_TEST), RightSign (DIAGNOSTIC_TEST), Case Control (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05227404?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI